Foghorn Therapeutics: BVF Partners may own about 14.3%

Ownership blockers prevented exercise of all reported pre-funded and Series warrants as of October 1, 2026.

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. (FHTX) reports that Biotechnology Value Fund, L.P. beneficially owned 4,494,462 shares (approximately 7.6%), Biotechnology Value Fund II, L.P. 3,232,448 shares (approximately 5.4%), and Biotechnology Value Trading Fund OS LP 619,258 shares (approximately 1.0%) as of the close of business on October 1, 2026. The percentages use 59,385,315 shares outstanding as of July 31, 2026.

BVF Partners L.P., BVF Inc. and Mark N. Lampert each may be deemed to beneficially own 8,507,000 shares (approximately 14.3%), including shares held in a managed account; these overlapping attributions are not separate blocks to add. The reporting persons and the managed account also held pre-funded warrants exercisable for 5,937,278 shares and Series 1 and Series 2 warrants exercisable for 1,862,891 shares each. The 9.99% blockers prohibited exercise of all such warrants as of October 1, 2026.

Key Figures

Beneficial ownership attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert: 8,507,000 shares Beneficial ownership percentage attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert: Approximately 14.3% BVF beneficial ownership: 4,494,462 shares +5 more

8 metrics

Beneficial ownership attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 8,507,000 shares Each may be deemed to own this amount as of the close of business on October 1, 2026

Beneficial ownership percentage attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert Approximately 14.3% Based on 59,385,315 shares outstanding as of July 31, 2026

BVF beneficial ownership 4,494,462 shares As of the close of business on October 1, 2026

BVF2 beneficial ownership 3,232,448 shares As of the close of business on October 1, 2026

Shares outstanding 59,385,315 shares As of July 31, 2026

Pre-funded warrants exercisable shares 5,937,278 shares Immediately exercisable at $0.0001 per share; the warrants do not expire

Series 1 Warrants 1,862,891 shares Immediately exercisable at $13.42 per share; expire June 30, 2027

Series 2 Warrants 1,862,891 shares Immediately exercisable at $20.13 per share; expire December 31, 2030

Key Terms

Pre-Funded Warrants, Pre-Funded Warrants Blocker, Series Warrants Blocker, beneficially owned

4 terms

Pre-Funded Warrants financial

"held pre-funded warrants exercisable for an aggregate of 5,937,278 Shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Pre-Funded Warrants Blocker financial

"the Pre-Funded Warrants Blocker prohibits the exercise"

Series Warrants Blocker financial

"the Series Warrants Blocker prohibits the exercise"

beneficially owned financial

"BVF beneficially owned 4,494,462 Shares"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FHTX shares did the reporting persons beneficially own?

BVF Partners L.P., BVF Inc. and Mark N. Lampert each may be deemed to beneficially own 8,507,000 shares, approximately 14.3%, as of the close of business on October 1, 2026. These are overlapping attributions of shares held by the funds and managed account, not separate positions to add.

Could holders exercise the FHTX warrants?

No. As of October 1, 2026, the blockers prohibited exercise of all pre-funded, Series 1 and Series 2 warrants held by the reporting persons and the Partners Managed Account. The blockers limit ownership to 9.99%; the pre-funded warrant language applies the limit immediately before or after exercise, while the Series Warrants blocker applies together with affiliates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 04:27 PM Accepted by SEC EDGAR 10/05/2026 - 04:27 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Foghorn Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

344174107

(CUSIP Number)

10/01/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND L P

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,494,462.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,494,462.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,494,462.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF I GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,494,462.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,494,462.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,494,462.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BIOTECHNOLOGY VALUE FUND II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,232,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,232,448.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,232,448.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF II GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,232,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,232,448.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,232,448.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

Biotechnology Value Trading Fund OS LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,258.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,258.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,258.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF Partners OS Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 619,258.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 619,258.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

619,258.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.0 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF GP HOLDINGS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,726,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,726,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,726,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

13.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF PARTNERS L P/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,507,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,507,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,507,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.3 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

BVF INC/IL

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,507,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,507,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,507,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.3 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP Number(s): 344174107

1

Names of Reporting Persons

LAMPERT MARK N

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,507,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,507,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,507,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.3 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Foghorn Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA 02139
Item 2.
(a)	Name of person filing: Biotechnology Value Fund, L.P. ("BVF") BVF I GP LLC ("BVF GP") Biotechnology Value Fund II, L.P. ("BVF2") BVF II GP LLC ("BVF2 GP") Biotechnology Value Trading Fund OS LP ("Trading Fund OS") BVF Partners OS Ltd. ("Partners OS") BVF GP Holdings LLC ("BVF GPH") BVF Partners L.P. ("Partners") BVF Inc. Mark N. Lampert ("Mr. Lampert") Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)	Address or principal business office or, if none, residence: Biotechnology Value Fund, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF I GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Fund II, L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF II GP LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 Biotechnology Value Trading Fund OS LP PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF Partners OS Ltd. PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands BVF GP Holdings LLC 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Partners L.P. 44 Montgomery St., 40th Floor San Francisco, California 94104 BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Mark N. Lampert 44 Montgomery St., 40th Floor San Francisco, California 94104
(c)	Citizenship: Biotechnology Value Fund, L.P. Delaware BVF I GP LLC Delaware Biotechnology Value Fund II, L.P. Delaware BVF II GP LLC Delaware Biotechnology Value Trading Fund OS LP Cayman Islands BVF Partners OS Ltd. Cayman Islands BVF GP Holdings LLC Delaware BVF Partners L.P. Delaware BVF Inc. Delaware Mark N. Lampert United States
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 344174107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on the date hereof, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held pre-funded warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 5,937,278 Shares, subject to the Pre-Funded Warrants Blocker (as defined and described below). The Pre-Funded Warrants are exercisable immediately, do not expire, and have an exercise price of $0.0001 per Share. A holder of Pre-Funded Warrants shall not have the right to exercise any portion of the Pre-Funded Warrants pursuant to the terms and conditions thereof and any such exercise shall be null and void and treated as if never made to the extent that immediately prior to or after giving effect to such exercise, such holder together with the other Attribution Parties (as defined in the Form of Pre-Funded Warrant to Purchase Common Stock) collectively would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to such exercise (the "Pre-Funded Warrants Blocker"). As of the close of business on the date hereof, the Pre-Funded Warrants Blocker prohibits the exercise of all of the Pre-Funded Warrants held by the Reporting Persons and in the Partners Managed Account. As of the close of business on the date hereof, the Reporting Persons and the Partners Managed Account held Series 1 Warrants (the "Series 1 Warrants") exercisable for an aggregate of 1,862,891 Shares, and Series 2 Warrants (the "Series 2 Warrants", and together with the Series 1 Warrants, the "Series Warrants") exercisable for an aggregate of 1,862,891 Shares, subject to the Series Warrants Blocker (as defined and described below). The Series 1 Warrants are exercisable immediately, expire on June 30, 2027, and have an exercise price of $13.42 per Share. The Series 2 Warrants are exercisable immediately, expire on December 31, 2030, and have an exercise price of $20.13 per Share. Each holder of Series Warrants will be prohibited from exercising such Series Warrant if, as a result of such exercise, the holder, together with its affiliates, would own more than 9.99% of the total number of Shares then issued and outstanding (the "Series Warrants Blocker"), subject to certain limited adjustments. As of the close of business on the date hereof, the Series Warrants Blocker prohibits the exercise of all of the Series Warrants held by the Reporting Persons and in the Partners Managed Account. As of the close of business on the date hereof, (i) BVF beneficially owned 4,494,462 Shares, excluding (a) 3,132,723 Shares underlying certain Pre-Funded Warrants held by it, (b) 1,022,635 Shares underlying the Series 1 Warrants held by it, and (c) 1,022,635 Shares underlying the Series 2 Warrants held by it; (ii) BVF2 beneficially owned 3,232,448 Shares, excluding (a) 2,394,331 Shares underlying the Pre-Funded Warrants held by it, (b) 703,630 Shares underlying the Series 1 Warrants held by it, and (c) 703,630 Shares underlying the Series 2 Warrants held by it; and (iii) Trading Fund OS beneficially owned 619,258 Shares, excluding (a) 313,925 Shares underlying the Pre-Funded Warrants held by it, (b) 109,394 Shares underlying the Series 1 Warrants held by it, and (c) 109,394 Shares underlying the Series 2 Warrants held by it. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,494,462 Shares beneficially owned by BVF. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,232,448 Shares beneficially owned by BVF2. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 619,258 Shares beneficially owned by Trading Fund OS. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 7,726,910 Shares beneficially owned in the aggregate by BVF and BVF2. Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 8,507,000 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 160,832 Shares held in the Partners Managed Account, which excludes (a) 96,299 Shares underlying the Pre-Funded Warrants, (b) 27,232 Shares underlying certain Series 1 Warrants, and (c) 27,232 Shares underlying certain Series 2 Warrants held in the Partners Managed Account. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,507,000 Shares beneficially owned by Partners. Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 8,507,000 Shares beneficially owned by BVF Inc. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
(b)	Percent of class: The following percentages are based upon 59,385,315 Shares outstanding as of July 31, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026. As of the close of business on the date hereof, (i) BVF beneficially owned approximately 7.6% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 5.4% of the outstanding Shares, (iii) Trading Fund OS beneficially owned approximately 1.0% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 7.6% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 5.4% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own approximately 1.0% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 13.0% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 14.3% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Cover Pages Items 5-9.
	(ii) Shared power to vote or to direct the vote: See Cover Pages Items 5-9.
	(iii) Sole power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
	(iv) Shared power to dispose or to direct the disposition of: See Cover Pages Items 5-9.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF 2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on May 30, 2024.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF I GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BIOTECHNOLOGY VALUE FUND II LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF II GP LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

Biotechnology Value Trading Fund OS LP

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF Partners OS Ltd.

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF GP HOLDINGS LLC

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF PARTNERS L P/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

BVF INC/IL

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert, Authorized Signatory
Date:	10/05/2026

LAMPERT MARK N

Signature:	/s/ Mark N. Lampert
Name/Title:	Mark N. Lampert
Date:	10/05/2026